Wells Fargo & Company MN increased its position in Fluidigm Co. (NASDAQ:FLDM) by 41.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 337,590 shares of the medical research company’s stock after buying an additional 99,137 shares during the period. Wells Fargo & Company MN’s holdings in Fluidigm were worth $4,159,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of FLDM. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Fluidigm in the second quarter worth about $68,000. BNP Paribas Arbitrage SA lifted its position in shares of Fluidigm by 3,543.1% in the first quarter. BNP Paribas Arbitrage SA now owns 6,849 shares of the medical research company’s stock worth $91,000 after buying an additional 6,661 shares in the last quarter. Aperio Group LLC purchased a new stake in shares of Fluidigm in the second quarter worth about $124,000. Bank of America Corp DE lifted its position in shares of Fluidigm by 149.3% in the fourth quarter. Bank of America Corp DE now owns 14,449 shares of the medical research company’s stock worth $125,000 after buying an additional 8,654 shares in the last quarter. Finally, SMH Capital Advisors Inc. bought a new stake in Fluidigm during the first quarter worth approximately $146,000.
Several brokerages have weighed in on FLDM. ValuEngine cut Fluidigm from a “buy” rating to a “hold” rating in a research note on Wednesday, June 12th. BidaskClub cut Fluidigm from a “hold” rating to a “sell” rating in a research note on Friday, August 16th. Finally, Zacks Investment Research raised Fluidigm from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a research note on Wednesday, July 3rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $14.75.
In other Fluidigm news, Director Samuel D. Colella bought 9,000 shares of the business’s stock in a transaction dated Wednesday, August 7th. The shares were purchased at an average price of $7.00 per share, with a total value of $63,000.00. Following the completion of the purchase, the director now owns 115,481 shares in the company, valued at approximately $808,367. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Levin Easterly Partners Llc sold 186,759 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $12.31, for a total value of $2,299,003.29. The disclosure for this sale can be found here. Over the last three months, insiders have acquired 15,000 shares of company stock worth $95,460 and have sold 2,018,179 shares worth $18,903,771. Insiders own 2.20% of the company’s stock.
NASDAQ FLDM traded down $0.14 during trading hours on Friday, hitting $5.66. 2,880 shares of the company were exchanged, compared to its average volume of 917,805. The stock has a 50-day moving average price of $6.29 and a 200 day moving average price of $10.94. The company has a quick ratio of 2.48, a current ratio of 2.86 and a debt-to-equity ratio of 0.32. Fluidigm Co. has a 52 week low of $5.06 and a 52 week high of $14.90. The stock has a market cap of $388.66 million, a PE ratio of -7.01 and a beta of 2.37.
Fluidigm (NASDAQ:FLDM) last issued its quarterly earnings data on Thursday, August 1st. The medical research company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.08). Fluidigm had a negative return on equity of 31.45% and a negative net margin of 57.48%. The company had revenue of $28.20 million for the quarter, compared to the consensus estimate of $30.16 million. Fluidigm’s quarterly revenue was up 6.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that Fluidigm Co. will post -0.55 earnings per share for the current year.
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.
Featured Article: Limitations of analyzing profit margin
Want to see what other hedge funds are holding FLDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fluidigm Co. (NASDAQ:FLDM).
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.